Banks are cutting New World a two-year lifeline on its $11B loan — buy the distressed-property relief bounce

Verdict: watch the lenders, don't chase the shares

**This is a thesis worth watching, not a trade worth taking today.** The strongest point for it is the catalyst itself: per Bloomberg's October 16 report, banks are in talks to extend New World's $11.2 billion loan by two years, with the piece flagging a possible capital injection — exactly the event that compresses default tail-risk for distressed developer equity. The strongest point against is that this is talks, not signatures: the extension and the injection are two stacked contingencies, and the supplied data could not map 17.HK to a fundamentals series, so there is no revenue, leverage, or cash-flow evidence to corroborate the balance-sheet case. Mechanically, the entry rules never fired across 60, 24, or 12 months of daily bars (1,233 evaluated bars), and the parameter-sensitivity review exceeded its time budget with no robust setup established, so there is no validated configuration to lean on. What would flip the verdict: a signed two-year extension, or a credible equity-injection announcement, followed by the same day showing the first support level holding with the 10-day rate-of-change turning positive and the 12/26 MACD crossing above its signal line. Until then, the honest scorecard says thesis first, mechanics second, balance sheet unseen. **Conviction breakdown** — thesis support 65 (the lender-negotiation narrative is well-sourced and timely), trade readiness 20 (no live signal), risk quality 35 (the rules define a 2:1 reward-to-risk geometry, but headline gap risk cuts both ways), trigger proximity 15 (the entry conditions are far from current prices per the stress context), fundamentals trend 30 (the series was unmappable, so we score on narrative alone, not zero).

Trade now

**Nothing to do yet — this is a watch-list setup, not a live signal.** The rules were evaluated on real daily bars for New World Development (17.HK) and did not open an entry, so the correct posture today is to track the levels rather than chase. The entry is a support-and-reversal test: the price must dip to touch the first support level and close back at or above it, the 10-day rate-of-change must turn positive, and the MACD line (12/26) must cross above its signal line — all on the same configured condition set. Until a day shows that support touch plus momentum confirmation, the trade does not exist. If the entry fires, the risk envelope is defined by the rules, not by feel: a hard stop closes the position at a 2% loss, or if the close crosses back below the second support level; the take-profit closes at a 4% gain, at the first resistance level, or when the 14-day RSI moves above 50 alongside an aged position (the 90-bar time exit is the backstop). That fixed 4%-gain versus 2%-loss geometry is the effective 2:1 reward-to-risk profile; the support-based exits can tighten either side depending on where the levels sit. "Wait" means concretely this: no position, no scaling in, no anticipation entries. The parameter-sensitivity review did not establish a robust alternative setup, so we trade the rules as written. The thesis — that a two-year loan extension would shrink default tail-risk and snap the shares back from oversold levels — only gets…

Scores

• Conviction score breakdown: 33
• Thesis support: 65
• Trade readiness: 20
• Risk quality: 35
• Trigger proximity: 15
• Fundamentals trend: 30

Watch items

• 17.HK — Price vs first support level
• 17.HK — 10-day rate-of-change
• 17.HK — MACD line (12/26) vs signal line
• 17.HK — Close vs second support level
• 17.HK — Loan extension negotiation status
• 17.HK — Capital injection announcement